Johns hopkins launches first home microdose psilocybin safety trial
NCT ID NCT06450210
First seen Feb 25, 2026
Summary
This early-stage study at Johns Hopkins University is testing whether very small, repeated doses of psilocybin (the active ingredient in magic mushrooms) are safe for healthy people to take at home. Twenty volunteers will receive four different microdoses and a placebo on separate days in a double-blind design. Researchers will monitor blood pressure, heart rate, sobriety, and mental status to determine which doses could be safely used outside a clinic.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHEDELIC EXPERIENCES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
5510 Nathan Shock Drive
RECRUITINGBaltimore, Maryland, 21224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
psilocybin trihydrate (microdose)
What this could lead to
If successful, this could show that very low doses of psilocybin are safe to take at home without medical supervision, paving the way for future studies on potential benefits.
What could go wrong
This is a very early Phase 1 safety study with only 20 healthy participants. It does not test whether microdosing actually helps any condition, and results may not apply to people with health issues.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.